Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center

Zeller, Thomas; Muenstedt, Karsten; Stoll, Christoph; Schweder, Janine; Senf, Bianca; Ruckhaeberle, Eugen; Becker, Sven; Serve, Hubert; Huebner, Jutta

doi:10.1007/s00432-012-1336-6

Cited by 102 publications

(92 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our survey, 71% of patients used biologically based CAM therapies, which is a much higher percentage than described before (10-30% [31,32]) but in line with other recent data from our group [33]. Among breast cancer patients of a German certified breast cancer center, we found one third to be at risk of drug interactions.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Online Survey of Cancer Patients on Complementary and Alternative Medicine

et al. 2014

View full text Add to dashboard Cite

Introduction: Complementary and alternative medicine (CAM) is often used by cancer patients, yet, communication with the oncologist is poor. The objective of our study was to gather information on patients' usage of CAM, source of information, and aims, in order to derive strategies to improve the communication between physicians and patients on this topic. Materials and Methods: An online survey was conducted by linking a standardized questionnaire to the largest internet portal for cancer patients in Germany. The questionnaire addresses CAM usage, disclosure to physicians, source of information, objectives for using CAM, and perceived reasons for cancer. Results: Of 170 participants, 77% were currently using CAM. Disclosure to a physician was rather high with 63% having informed their oncologist. Asked whether the oncologist took time to discuss CAM, 74% answered ‘no'. Most frequently used are biologically based therapies, relaxation techniques, prayer, and meditation. Most patients want to reduce side effects, boost their immune system, and get active. Almost half the participants had positive experiences with some type of CAM before they fell ill. Conclusion: Understanding patients' concepts of the etiology of cancer and accepting their goals for using CAM may help oncologists communicate with their patients and guide them to a safe use of CAM.

show abstract

Section: Discussionsupporting

confidence: 90%

“…This questionnaire has been used in several oncological projects, and continues to be adapted to specific subtopics [25,26,27]. The first section of the questionnaire provides questions on the type of cancer and treatment.…”

Section: Methodsmentioning

confidence: 99%

Online Survey of Cancer Patients on Complementary and Alternative Medicine

et al. 2014

View full text Add to dashboard Cite

show abstract

“…At the MTD and lower-dose cohort, the combination of lenvatinib and cellular immunotherapy was associated with manageable toxicity. Treatment-related AEs were consistent with class effects typical of VEGFR-targeted therapy and immunotherapy (32). A previous study indicates that fatigue, mucosal inflammation, proteinuria, hypertension, as well as gastrointestinal toxicity, occurred at a low frequency (32).…”

Section: Discussionsupporting

confidence: 65%

“…Treatment-related AEs were consistent with class effects typical of VEGFR-targeted therapy and immunotherapy (32). A previous study indicates that fatigue, mucosal inflammation, proteinuria, hypertension, as well as gastrointestinal toxicity, occurred at a low frequency (32). Another previous study indicated that proteinuria, hypertriglyceridemia, diarrhea, and fatigue were the most common treatment-related TEAEs (33).…”

Section: Discussionmentioning

confidence: 59%

Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma

Cai

Tang

Shen

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Lenvatinib is an oral, multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor β, RET and KIT. Cellular immunotherapy has the potential to be a highly targeted treatment, with low toxicity to normal tissues and a high capacity to eradicate tumor tissue. The present study assessed the safety, maximum tolerated dose (MTD) and preliminary antitumor activity of lenvatinib and cellular immunotherapy in a murine model of renal cell carcinoma (RCC). The present study used a therapeutic dose of 0.12 mg lenvatinib and/or 10 4 rat uterine cancer adenocarcinoma (RuCa)-sensitized lymphocytes administered once daily continuously in 7-day cycles. Tumor regression was observed in mice with RCC following treatment with lenvatinib and 10 4 RuCa-sensitized lymphocytes. MTD was established as once daily administration of 0.18 mg lenvatinib and 10 6 RuCa-sensitized lymphocytes. The most common treatment-related adverse effects observed were fatigue (40%), mucosal inflammation (30%), proteinuria, diarrhea, vomiting, hypertension and nausea (all 40%). Combination therapy using lenvatinib and cellular immunotherapy enhanced the antitumor effect induced by single treatments and prolonged the survival of mice with RCC compared with either of the single treatments. Treatment with lenvatinib (0.12 mg) combined with 10 4

show abstract

“…The obtained data are consistent with studies conducted by Ebel et al 12 Other studies show that 52% of cancer patients use at least one form of complementary medicine, and 77% of them use herbal OTC medicines, dietary supplements and vitamins. 13 Research by Alsanad et al, conducted in the UK, indicate that adult cancer patients use herbal preparations (3.1% -21.8%) simultaneously with pharmacotherapy. 7,14 In less developed countries a higher percentage of patients use herbal OTC drugs or dietary supplements, e.g.…”

Section: Discussionmentioning

confidence: 99%

Use of the Herbal OTC Products and Dietary Supplements by Patients Receiving Chemotherapy: Survey-Based Study

Kowalczyk¹,

Bodalska²,

Boszkiewicz³

et al. 2017

IJPER

View full text Add to dashboard Cite

Context: Among cancer patients receiving chemotherapy, there is a growing trend to use self-medication. Many of them take preparations sold over the counter (OTC) and dietary supplements containing plant raw materials. Aims: The aim of this study is to evaluate the herbal OTC drug and dietary supplement usage among patients treated on the chemotherapy ward. Settings and Design: An anonymous survey was conducted among 92 patients of the chemotherapy ward of the Lower Silesian Oncology Center in Wroclaw (Poland) with the approval of the Bioethical Commission of the Medical University in Wroclaw (no KB-562/2014) and The Declaration of Helsinki. Methods and Material: An anonymous survey was conducted among 92 patients of the chemotherapy ward of the Lower Silesian Oncology Center in Wroclaw (Poland) in 2015. The questions concerned the use of herbal preparations by patients during chemotherapy. Statistical analysis used: The statistical analysis was developed using programs: Microsoft Office Excel 2007 and STATISTICA 10 (StarSoft Inc.). Analysis was performed by χ2 test. Results: The study has confirmed that the use of herbal OTC products and dietary supplements among cancer patients is a common occurrence. The main source of information about herbal preparations is the Internet and the most common place of purchase is a pharmacy. Conclusions: It is necessary to educate cancer patients to increase their awareness of the importance of a doctor's knowledge about all preparations that they take. Pharmacists play a very important role in self-medication of the patients. Thus, pharmacy students' education is needed in this field as well.

show abstract

Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center

Cited by 102 publications

References 11 publications

Online Survey of Cancer Patients on Complementary and Alternative Medicine

Online Survey of Cancer Patients on Complementary and Alternative Medicine

Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma

Use of the Herbal OTC Products and Dietary Supplements by Patients Receiving Chemotherapy: Survey-Based Study

Contact Info

Product

Resources

About